About us
Since its creation in 2016, H4 Orphan Pharma has been working every day to develop innovative treatments to treat patients with fibrotic diseases with unmet medical needs in the field of:
- respiratory diseases
- ophthalmologic diseases
The company is currently developing two drug candidates targeting:
- idiopathic pulmonary fibrosis
- dry eye, including Gougerot-Sjögren’s syndrome
Our vision
We are focusing our efforts on severe, chronic fibrotic diseases with no satisfactory therapeutic solution, with the ambition of bringing safe and effective therapies to market. We believe that fibrotic diseases are multifactorial and require compounds that act at different levels at the same time.
Our mission
We are dedicated to finalise the clinical development of our first drug candidate in idiopathic pulmonary fibrosis and bring it to market as quickly as possible. The Belgian medicines agency has given a positive scientific advice to enter Phase 2 for IPF. To achieve this, we are drawing from the strong pharmaceutical and medical expertise of our team, which built a new development model based on optimised resources.
We work with the best international experts in the chemical, pharmacological, toxicological and clinical fields.